- Home
- WFG vs BLCO Comparison
WFG vs BLCO Comparison
Compare WFG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- BLCO
- Stock Information
- Founded
- WFG 1955
- BLCO 1853
- Country
- WFG Canada
- BLCO Canada
- Employees
- WFG N/A
- BLCO N/A
- Industry
- WFG
- BLCO Ophthalmic Goods
- Sector
- WFG
- BLCO Health Care
- Exchange
- WFG Nasdaq
- BLCO Nasdaq
- Market Cap
- WFG 7.5B
- BLCO 7.0B
- IPO Year
- WFG N/A
- BLCO 2022
- Fundamental
- Price
- WFG $87.80
- BLCO $18.88
- Analyst Decision
- WFG Buy
- BLCO Buy
- Analyst Count
- WFG 4
- BLCO 12
- Target Price
- WFG $106.25
- BLCO $20.91
- AVG Volume (30 Days)
- WFG 144.8K
- BLCO 488.4K
- Earning Date
- WFG 02-12-2025
- BLCO 10-30-2024
- Dividend Yield
- WFG 1.46%
- BLCO N/A
- EPS Growth
- WFG N/A
- BLCO N/A
- EPS
- WFG N/A
- BLCO N/A
- Revenue
- WFG $6,283,000,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- WFG N/A
- BLCO $17.39
- Revenue Next Year
- WFG $6.67
- BLCO $6.18
- P/E Ratio
- WFG N/A
- BLCO N/A
- Revenue Growth
- WFG N/A
- BLCO 18.01
- 52 Week Low
- WFG $73.91
- BLCO $13.16
- 52 Week High
- WFG $102.40
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- WFG 33.10
- BLCO 43.60
- Support Level
- WFG $91.92
- BLCO $17.71
- Resistance Level
- WFG $94.18
- BLCO $18.76
- Average True Range (ATR)
- WFG 2.27
- BLCO 0.49
- MACD
- WFG -0.87
- BLCO -0.13
- Stochastic Oscillator
- WFG 11.28
- BLCO 39.00
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board, or OSB, producers in the world.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.